The human CLDN18.2 coding sequence was inserted into the ROSA26 locus in MC38 cells. Human CLDN18.2 is highly expressed on the surface of B-hCLDN18.2 MC38 cells.

B-hCLDN18.2 MC38 cells have the capability to establish tumors in vivo and can be used for efficacy studies.

CLDN18.2 expression analysis in B-hCLDN18.2 MC38 cells by flow cytometry. Single cell suspensions from wild-type MC38 and B-hCLDN18.2 MC38 cultures were stained with species-specific anti-CLDN18.2 antibody. Human CLDN18.2 was detected on the surface of B-hCLDN18.2 MC38 cells but not wild-type MC38 cells. The 1-F6 clone of B-hCLDN18.2 MC38 cells was used for in vivo experiments.

Subcutaneous homograft tumor growth of B-hCLDN18.2 MC38 cells. B-hCLDN18.2 MC38 cells (5x10⁵) and wild-type MC38 cells (5x10⁵) were subcutaneously implanted into C57BL/6 mice (female, n=5). Tumor volume and body weight were measured twice a week. (A) Average tumor volume ± SEM. (B)  Body weight (Mean± SEM). Volume was expressed in mm³ using the formula: V=0.5 X long diameter X short diameter². As shown in panel A, B-hCLDN18.2 MC38 cells were able to establish tumors in vivo and can be used for efficacy studies.